NCT00785460已完成3 期
Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers
Ruhr University of Bochum1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Flow mediated dilatation
研究概览
简要总结
Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.
详细描述
Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation (FMD) of the brachial arteryand laboratory parameters (adhesion molecules).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Single
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy habitual smokers
排除标准
- •any kind of chronic disease
研究组 & 干预措施
Benfotiamine and Smoking
Experimental
干预措施: Benfotiamine (Drug)
Smoking alone
Placebo Comparator
干预措施: Benfotiamine (Drug)
结局指标
主要结局
Flow mediated dilatation
时间窗: 3 days
次要结局
- Laboratory markers of endothelial function(3 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00446810Ruhr University of Bochum30
已完成
1 期
Effects of Vitamin B1 in Type 1 Diabetic PatientsDiabetes Mellitus, Type 1NCT00117026University Hospital, Aker67
已完成
4 期
Benfotiamine in Diabetic NephropathyDiabetic NephropathyNCT00565318University Medical Center Groningen86
已完成
1 期
Preventive effect of vascular function deterioration after hemiplegic cerebral vascular accident adjustments affect activity and sleep patternsCerebrovascular diseaseJPRN-UMIN000009505Kimura Akira labo, Gunma PAZ College10
已完成
4 期
High Dose Vitamin B1 to Reduce Abusive Alcohol UseAlcoholismNCT00680121University of Kansas120